According to Fortune Business Insights, the global AI in bioinformatics market size was valued at USD 1.06 billion in 2025. The market is projected to grow from USD 1.22 billion in 2026 to USD 4.80 billion by 2034, exhibiting a CAGR of 18.63% during the forecast period. North America dominated the AI in bioinformatics market with a market share of 41.51% in 2025.
The AI in bioinformatics market is gaining momentum as artificial intelligence technologies are increasingly integrated into biological data analysis, drug discovery, genomic research, precision medicine, and other life science applications. The growing volume and complexity of biological datasets is encouraging researchers and organizations to adopt AI-driven tools for faster and more efficient interpretation.
Continue reading for more details:
https://www.fortunebusinessinsights.com/ai-in-bioinformatics-market-115851
Market Segmentation
The AI in bioinformatics market can be segmented based on component, technology, application, end user, and geography. Based on component, the market includes software and services. AI-enabled software assists researchers in processing, analyzing, and interpreting complex biological datasets, while services support implementation, integration, consulting, maintenance, and specialized analytical requirements. By technology, the market includes machine learning, deep learning, natural language processing, computer vision, and other AI technologies. Machine learning and deep learning are increasingly used for identifying patterns in genomic and molecular datasets, while natural language processing can support the extraction of information from scientific literature and biological databases. Based on application, the AI in bioinformatics market covers drug discovery and development, genomics, proteomics, metabolomics, precision medicine, clinical research, and other applications. Drug discovery is an important application because AI can assist researchers in identifying potential drug candidates and analyzing molecular interactions. Genomics is also gaining attention as AI can support sequence analysis, variant interpretation, and biological data processing. Based on end user, the market includes pharmaceutical and biotechnology companies, academic and research institutions, healthcare organizations, and other users.
Key Players
- NVIDIA Corporation
- IBM Corporation
- Microsoft Corporation
- Google LLC
- Intel Corporation
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- QIAGEN N.V.
- Dassault Systèmes
- Schrödinger, Inc.
Market Growth
The AI in bioinformatics market is experiencing strong development as life science organizations increasingly rely on computational technologies to process complex biological information. The rapid expansion of genomic, proteomic, molecular, and clinical datasets has created a growing need for advanced analytical systems capable of identifying meaningful patterns and relationships. Artificial intelligence can help researchers automate repetitive analytical processes, improve data interpretation, and support decision-making throughout research workflows. Drug discovery is an important growth area because pharmaceutical and biotechnology companies are exploring AI-powered approaches to identify potential therapeutic candidates, evaluate molecular characteristics, and optimize research processes. AI is also supporting target identification, molecular modeling, biomarker discovery, and other activities associated with pharmaceutical research. The growing adoption of precision medicine is further creating opportunities for AI in bioinformatics. Researchers and healthcare organizations are increasingly interested in analyzing biological information to support more personalized approaches to disease understanding and treatment selection. Advances in machine learning and deep learning are improving the ability of computational systems to process large and complex biological datasets. Natural language processing is also creating opportunities by enabling the analysis of scientific publications, clinical information, and other text-based resources. The increasing availability of cloud computing infrastructure is supporting AI adoption by providing scalable computational capabilities for research organizations and businesses. Collaboration between technology companies, pharmaceutical firms, biotechnology companies, universities, and research institutions is also encouraging innovation. These collaborations can accelerate the development of AI-powered bioinformatics platforms and expand their application across different areas of life science research. As organizations continue to prioritize data-driven research and technological innovation, the AI in bioinformatics market is expected to benefit from increasing adoption across pharmaceutical, biotechnology, healthcare, and academic environments.
Restraining Factors
The AI in bioinformatics market faces several challenges despite its growth potential. One major concern is the complexity and quality of biological data. Biological datasets can be highly diverse, heterogeneous, and difficult to standardize, which may affect the performance and reliability of AI models. Incomplete or inconsistent datasets can make it challenging for researchers to generate accurate and reproducible results. Data privacy and security are also important considerations, particularly when AI systems process genomic, clinical, or other sensitive biological information. Organizations need appropriate safeguards to protect data and ensure compliance with relevant requirements. Another challenge is the shortage of professionals who possess expertise in both artificial intelligence and bioinformatics. Developing, validating, deploying, and maintaining advanced AI systems requires specialized knowledge across computational science, biology, statistics, and data engineering. The implementation of AI solutions can also require significant investments in computing infrastructure, software, data management, and workforce training. Integration with existing bioinformatics platforms and research workflows may be technically complex. In addition, the interpretability of AI-generated results can present challenges because some advanced models operate as complex systems that may be difficult for researchers to understand or validate. Concerns regarding model bias, reproducibility, data compatibility, and the reliability of AI-generated insights may also influence adoption. Addressing these challenges through improved data standards, explainable AI approaches, secure infrastructure, specialized training, and stronger collaboration between technology and life science organizations will be important for the continued development of the AI in bioinformatics market.
Regional Analysis
North America is a leading region in the AI in bioinformatics market, supported by advanced biotechnology capabilities, strong research infrastructure, established pharmaceutical companies, and significant adoption of artificial intelligence technologies. The presence of technology providers, academic institutions, research organizations, and healthcare companies creates a strong ecosystem for developing and implementing AI-driven bioinformatics solutions. Growing investments in genomics, drug discovery, precision medicine, and computational biology are also supporting regional market development.
Europe represents an important market supported by established life science research capabilities and increasing interest in artificial intelligence for biological data analysis. Pharmaceutical companies, biotechnology firms, universities, and research organizations are adopting computational approaches to improve research efficiency. The region's emphasis on scientific innovation, personalized medicine, and advanced healthcare technologies is creating opportunities for AI-enabled bioinformatics applications.
Asia Pacific is witnessing increasing adoption of AI in bioinformatics as biotechnology research, pharmaceutical development, healthcare digitization, and genomics activities continue to expand. Growing investments in artificial intelligence and life science technologies are encouraging organizations to develop advanced analytical capabilities. Increasing collaboration among research institutions, technology companies, and pharmaceutical organizations is also supporting innovation across the region.
Latin America offers emerging opportunities as healthcare systems, biotechnology capabilities, and digital research infrastructure continue to develop. Increasing interest in genomic research and data-driven healthcare is creating opportunities for AI-enabled bioinformatics solutions. Organizations are gradually exploring computational technologies to improve biological research and analytical workflows.
The Middle East & Africa region is also developing opportunities through investments in healthcare modernization, biotechnology research, digital technologies, and advanced analytical capabilities. Increasing interest in genomics, precision medicine, and data-driven healthcare can support the adoption of AI-based bioinformatics solutions. Overall, the AI in bioinformatics market in 2026 is being shaped by advances in artificial intelligence, expanding biological datasets, drug discovery requirements, genomic research, precision medicine, cloud computing, and growing collaboration between technology and life science organizations.
Uncover Japan’s Market Trends - Explore the Latest -AI in Bioinformatics Market - Insights-